Opinion|Videos|July 10, 2024
Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024
Dr Garfall, MD, provides insights following results derived from the MajesTEC-1 study.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the data you presented at the 2024 ASCO Annual Meeting on long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM).
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home
2
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS
3
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
4
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
5